Skip to main
IBIO

iBio (IBIO) Stock Forecast & Price Target

iBio (IBIO) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 60%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

iBio is a preclinical stage biotechnology company with a solid pipeline of next-generation biopharmaceuticals that target hard-to-treat cancers and other chronic diseases. Using their proprietary AI technology and 3D-modeling, iBio aims to minimize downstream risks and decrease drug development timelines, potentially leading to increased success and revenue for the company. However, investors should be aware of potential risks including uncertainties surrounding the protection of iBio's intellectual property, the need for additional funding, and the clinical and regulatory risks associated with their product candidates.

Bears say

iBio is a preclinical biotech company with positive preclinical data on their antibody IBIO-610 and plans to file for regulatory approval soon, however, there is fierce competition in the space, potential need for future fundraising, and risks associated with their development pipeline and regulatory processes.

iBio (IBIO) has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 60% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of iBio and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About iBio (IBIO) Forecast

Analysts have given iBio (IBIO) a Buy based on their latest research and market trends.

According to 5 analysts, iBio (IBIO) has a Buy consensus rating as of Jul 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

iBio (IBIO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.